Review of Cardiovascular Drugs Under Workers’ Comp Claims
Summary
Cardiovascular drugs rarely appear in workers’ comp, but when an injury triggers the need—through surgery, clot prevention, physiological stress, or unmasked cardiometabolic risk—they instantly become high-stakes medications that demand real clinical oversight. These aren’t routine scripts: DOACs, SGLT2 inhibitors, PCSK9 inhibitors, and Omega-3 therapies carry complex risks, significant interactions, and long clinical tails. Managing them correctly protects the claimant, stabilizes recovery, and prevents complications that can dramatically alter the trajectory of a claim.
—
Cardiovascular drugs aren’t the first thing anyone thinks about when a workers’ comp claim opens. And in fairness—most of the time, they shouldn’t be. These medications typically sit outside the core injury care pathway.
But here’s the nuance adjusters and payers can’t afford to miss:
When an injury triggers the need for cardiovascular therapy—even temporarily—it becomes one of the highest-risk, highest-impact medication categories in the entire claim.
These aren’t casual scripts. They’re clinical inflection points—moments that require precision, oversight, and a PBM that knows how to manage medications far beyond pain and inflammation.
Let’s break down when and why cardiovascular drugs enter workers’ comp, what to expect, and why modern claims occasionally involve complex, mostly-brand therapies that demand true clinical management.
Surgery
Orthopedic and spine surgeries often force providers to assess cardiac risk—even in workers’ comp claimants with no known cardiac history. A few common ways cardiovascular drugs enter the picture:
Perioperative blood pressure management
Stress, anesthesia, and pain can push blood pressure higher than baseline. Short-term antihypertensive therapy may be initiated pre- or post-op.
Prevention of surgical complications
Some patients with risk factors require specific cardiovascular management to reduce perioperative risk—especially older or deconditioned workers.
Restarting chronic meds safely
For claimants with existing cardiovascular disease, the risk isn’t starting the drug—it’s pausing it. ACE inhibitors, beta-blockers, and statins often need coordinated continuation during admission and surgical recovery.
Even brief lapses can alter surgical outcomes, delay post-operative therapy, or trigger destabilizing symptoms.
Post-Surgical Clot Prevention: High-Risk, High-Impact Medications
Immobilization, inflammation, and surgery all raise clot risk—especially in lower extremity injuries or complex orthopedic recoveries. This is where workers’ comp sees one of the most clinically significant but least frequent medication classes:
Direct-Acting Oral Anticoagulants (DOACs)
Examples: Eliquis (apixaban), Xarelto (rivaroxaban)
These drugs are powerful. Effective. Convenient.
But they are also: high-cost, sensitive to timing, dependent on precise dosing, and risky if not managed correctly with post-op meds.
A DOAC in a comp claim is an immediate flag for clinical oversight, not cost management. One missed dose or one dangerous interaction can turn an immobilization risk into a life-threatening event.
Stress-Driven Cardiovascular Instability
Trauma, surgery, pain, and prolonged recovery create physiological stress.
For some workers, that stress becomes the tipping point for cardiovascular symptoms that didn’t appear before: elevated blood pressure, tachycardia, anxiety-induced BP surges, and abnormal cardiac markers.
This can lead to short-term initiation of: beta-blockers, ACE inhibitors, calcium channel blockers and other rate-control agents. And while these medications may be discontinued later, they are not low-stakes while they are active. They can impact pain tolerance, therapy capacity, and return-to-work readiness. Therefore, they must be managed intentionally—not allowed to float in the background of a claim.
The New Frontier: High-Cost Cardiometabolic Drugs
While rare, modern clinical practice increasingly blurs the line between metabolic risk and cardiovascular protection. When an injured worker develops complications related to immobility, inflammation, or unmasked comorbidities, certain high-cost therapies may appear on a comp claim.
These medications require true clinical oversight, not simply adjudication:
SGLT2 Inhibitors (Jardiance, Farxiga)
Commonly used for diabetes but increasingly prescribed for cardiac and renal protection.
In comp, they may be initiated when injury recovery reveals underlying cardiometabolic risk.
PCSK9 Inhibitors (Repatha, Praluent)
Potent injectable lipid-lowering drugs for patients with severe hyperlipidemia not controlled through statins.
In comp, these typically emerge after cardiac instability during recovery or a significant cardiac event.
Omega-3 Ethyl Esters (Vascepa)
Used for hypertriglyceridemia and cardiovascular risk reduction.
May enter the claim when inflammatory markers elevate during prolonged immobilization or recovery.
These are not medications you want managed by a PBM that only knows how to fill ibuprofen.
Why Maintenance Cardiovascular Drugs Have a Long Tail in Claims
Once cardiovascular drugs enter a claim—even if the trigger was injury-related—the tail can be long. They may extend:
through surgery prep
into post-operative rehab
throughout immobilization risk periods
during periods of chronic pain or delayed recovery
through psychological or physiological stress phases
And every one of those phases carries clinical risk if the therapy isn’t actively managed.
This is where Prodigy stands apart.
Our model isn’t built around watching unit costs—it’s built around ensuring:
correct initiation
appropriate duration
detection of drug-drug interactions
safe NSAID and analgesic pairing
monitoring of high-cost specialty cardiometabolic agents
and transparent reporting so payers understand exactly why a cardiovascular drug is on a comp claim
A cardiovascular drug may be rare in comp.
But rare events often define the trajectory of the claim.
Bottom Line
Cardiovascular medications aren’t everyday workers’ comp drugs.
They show up when the claim takes a clinical turn—surgery, clot risk, metabolic instability, stress-induced BP spikes, or emerging cardiometabolic complications.
When they do show up, they demand:
sharper oversight
tighter coordination
deeper clinical understanding
and a PBM prepared to manage medications far more complex than NSAIDs and muscle relaxers
These drugs may be infrequent, but they carry the longest clinical tail and the greatest potential to change the course of a recovery.
At Prodigy, we manage them with the seriousness they deserve—because in workers’ comp, the rare events are often the ones that matter most.
By Prodigy PharmDs
For questions, e-mail pharmd@prodigyrx.com
Citations
ACC/AHA Guidelines for perioperative cardiovascular management in non-cardiac surgery (2024).CHEST Guideline for VTE prevention in orthopedic surgery (2023).American Heart Association: Stress and cardiovascular response patterns.NEJM: Cardiometabolic drug advancements (SGLT2 inhibitors, PCSK9 inhibitors, 2023–2024 updates).FDA Approvals Database: DOACs and specialty cardiometabolic therapy indications.